After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects | The company doubled sales of its Biogen-partnered Alzheimer's disease treatment during its 2025 fiscal year.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the…
Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Doceree has bold ambitions to bring a new software category to pharma brand teams, one that reshapes campaign deployment in the…
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…
BeOne wins FDA approval in lymphoma race
